Physician profile
Larry Jankelowitz
NPI 1184794281
$3,871.46
in general payments reported to CMS, 2019-2025
31 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $241 · 2021: $343 · 2022: $431 · 2023: $572 · 2024: $686 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.24 |
| Education | $102.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $824.68 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $426.13 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $421.44 | 2019-2025 | Fasenra, Airsupra |
| Inari Medical, INC. | $390.36 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Enterprises LLC | $192.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $160.54 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.63 | 2022-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $116.09 | 2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $114.44 | 2024 | Sapien 3 Ultra Resilia |
| Abiomed | $109.49 | 2023 | Impella |
| Livanova USA, INC. | $104.02 | 2023 | Lifesparc |
| Electromed, INC. | $88.79 | 2021-2025 | Smartvest |
| Philips North America LLC | $83.04 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Inspire Medical Systems, INC. | $81.22 | 2023-2025 | Inspire |
| Grifols USA, LLC | $73.95 | 2019-2025 | Prolastin-C Liquid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.86 | 2022-2025 | Tezspire |
| Circassia INC. | $64.22 | 2019-2025 | Niox |
| Mylan Specialty L.P. | $51.64 | 2019-2024 | Yupelri |
| Insmed, INC. | $50.15 | 2025 | Brinsupri, Arikayce |
| La Jolla Pharmaceutical Company | $46.07 | 2019-2023 | Giapreza |
| Ge Healthcare | $38.68 | 2020 | |
| Chiesi USA, INC. | $37.41 | 2021 | |
| Vifor Pharma, INC. | $34.08 | 2024 | Zemaira |
| Shionogi INC | $33.03 | 2024 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $24.82 | 2025 | Glassia |
| Viatris Specialty LLC | $24.74 | 2025 | Yupelri |
| Tactile Systems Technology INC | $22.98 | 2025 | Flexitouch Plus, Nimbl |
| Ceribell, INC. | $22.97 | 2024 | Pocket Eeg Device |
| Baxter Healthcare | $20.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.54 | 2019 | |
| Allergan, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Jankelowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.